home / stock / mrus / mrus news

MRUS News and Press, Merus N.V. From 05/03/21

Stock Information
Company Name: Merus N.V.
Stock Symbol: MRUS
Market: NASDAQ
Website: merus.nl
Menu
MRUS MRUS Quote MRUS Short MRUS News MRUS Articles MRUS Message Board
Get MRUS Alerts

News, Short Squeeze, Breakout and More Instantly...
MRUS - Merus Announces First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advanced Lung Cancer and Other Solid Tumors

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific ...
MRUS - Zenocutuzumab Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecif...

MRUS - Merus EPS misses by $0.28, beats on revenue

Merus (MRUS): FY GAAP EPS of -$2.92 misses by $0.28.Revenue of $29.94M (-3.8% Y/Y) beats by $1.31M.Press Release For further details see: Merus EPS misses by $0.28, beats on revenue

MRUS - Merus Announces Financial Results for the Fourth Quarter and Full Year 2020 and Provides Business Update

Clinical data and program update planned for lead program zenocutuzumab (“Zeno”) in 2Q 2021 Clinical update planned for MCLA-145 in 2H 2021 MCLA-129 expected to enter clinic in the United States in 2021 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Mar...
MRUS - Merus Announces Poster Presentations for Zenocutuzumab and MCLA-129 at the American Association for Cancer Research 2021 Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecifi...

MRUS - Merus to Participate in a Fireside Chat at the 33rd Annual Roth Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 08, 2021 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundbe...

MRUS - Merus to Participate in Upcoming Investor Conferences

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced that Bill Lundberg, M.D., ...
MRUS - Merus prices $120M public offering

Merus ([[MRUS]] +1.3%) prices an underwritten public offering of 4.85M common shares at a public offering price of $24.75 per share.Gross proceeds expected to be ~$120M.Offering is expected to close on or about January 25, 2021.Company intends to use the net proceeds to advance the clinical d...

MRUS - Merus down 3% after announcing equity offer

Merus N.V. (NASDAQ:MRUS) intends to offer and sell up to $60M of shares of its common stock in an underwritten public offering.Underwriters have a 30-day option to purchase up to an additional $9M worth of stock.The company intends to use the net proceeds from this offering to advance the cli...

MRUS - Merus N.V. Announces Proposed Public Offering of Common Shares

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® ...
Previous 10 Next 10